An evaluation of neoadjuvant chemoradiotherapy for patients with resectable pancreatic ductal adenocarcinoma.
Conclusions. The treatment of NCRT followed by PD in patients with PDAC has a significantly lower rate of locoregional recurrence and a longer overall survival than those with surgery alone.
PMID: 23864756 [PubMed]
Source: HPB Surgery - Category: Surgery Tags: HPB Surg Source Type: research
More News: Adenocarcinoma | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Statistics | Study | Surgery